

CURRICULUM VITAE

Pilar M. Dominguez, PhD

pilar.dominguez@univ-cotedazur.fr

ORCID : 0000-0002-5775-4351

[linkedin.com/in/pilar-dominguez-rodriguez-3039b435](https://www.linkedin.com/in/pilar-dominguez-rodriguez-3039b435)

EDUCATION

- Ph.D. in Molecular Biology, Universidad Autonoma de Madrid, Spain 2005 – 2011
Supervisor: Carlos Ardavin
Project: Regulation by statins of the activation of inflammatory dendritic cells
- Master's degree in Biochemistry, Universidad de Zaragoza, Spain 2003 – 2005
- Master's degree in Chemistry, Universidad de Zaragoza, Spain 1998 – 2003

Other diplomas:

Animal experimentation diploma Level B (*Concepteur de projets*) 2023

PROFESSIONAL ACTIVITIES

- | | |
|-----------------|---|
| 01/2024-present | CRCN INSERM Researcher
Inserm U1065 (C3M) Université Côte d'Azur, Nice. |
| 01/2023-present | Leader “Cancer epigenetics and immunotherapy” team,
Inserm U1065 (C3M) Université Côte d'Azur, Nice.
The team belongs to Labex Signalife and Idex UCA ^{Jedi} (french government “Investments for the Future” and excellence programs).
<i>Publications:</i> 4 articles (1 senior author) |
| 07/2018-12/2022 | Senior Research Officer,
Peter MacCallum Cancer Centre, Melbourne, Australia
<i>Supervisor:</i> Ricky Johnstone
<i>Project:</i> Targeting deregulated epigenetic mechanisms in lymphoma and leukemia.
<i>Publications:</i> 4 articles (1 senior author) |
| 06/2013-05/2018 | Postdoctoral Associate,
Weill Cornell Medicine, New York, USA
<i>Supervisor:</i> Ari Melnick
<i>Project:</i> Role of TET proteins in mature B cells and lymphoma
<i>Publications:</i> 5 articles, 3 reviews (6 first author) |
| 02/2011-03/2013 | Postdoctoral Researcher,
Universidad Autonoma de Madrid, Spain |

Supervisor: Carlos Ardavin
Project: Epigenetic regulation of monocyte-derived dendritic cells
Publications: 3 articles, 1 review (3 first author)

OTHER EXPERIENCE

Awards

- 2024 'Young Researcher In Cancerology' Award Provence Alpes Cote d'Azur (PACA) Region (€130,637)
- 2020 'Lea Medal Award' for emerging female mid-career researchers (AU\$10,000)
- 2020 Australian and New Zealand Society for Immunology. *Carer's Award* (AU\$1000)

Invited Talks:

- 2024 Club Hématopoïèse et Oncogénèse (CHO) Meeting, Giens (France)
- 2024 C3M Symposium, Nice (France)
- 2024 Labex SIGNALIFE Conference, Nice (France)
- 2023 GRK2158 Scientific Colloquium, University of Düsseldorf (Germany)
- 2023 Cancerôpole 2023 Annual Seminar, Saint-Raphaël (France)
- 2021 WEHI Blood Cells and Blood Cancer Division Seminars, Melbourne (Australia)
- 2021 Olivia-Newton John Cancer Research Institute (ONJCRI) Cross-Institute Seminar Series, Melbourne (Australia)
- 2019 Monash Haematology Journal Club, Melbourne (Australia)

DIRECTION AND SCIENTIFIC ANIMATION

I lead the 'Cancer Epigenetics and Immunotherapy' team at C3M composed of:

Emilio Manuel SERRANO-LOPEZ : Postdoc

Calixte CALAUD : 2nd year PhD student

Abdelillah MAARAD: 2nd year PhD student

Thomas MARDIVIRIN : IE, CDD

Coralie DUPONT : IE, CDD

Corinne MENIGOT : AI, CDD

Supervision of research projects

Ongoing:

2024-2027 : Thesis, Calixte CALAUD “Investigation of combinatorial epigenetic therapies to treat lymphomas”

2024-2027: Thesis, Abdelillah MAARAD “Studying deregulated epigenetic mechanisms in lymphoma”

2024-2028: Postdoctoral project, Emilio Manuel SERRANO-LOPEZ “Epigenetic signaling in blood cancer”

2025-2026: Master 1, Océne ZINSOU “Studying the interactions between the tumor and the immune system in lymphoma”

2025-2026: Master 1, Saranur AYYILDIZ “Study of the response to epigenetic drugs in lymphoma”

Past:

2024-2025: Master 1, Killian GUIRAUD “Bioinformatics analysis of the effect of epigenetic therapies in lymphoma”

2023-2024: Master 2, Abdelillah MAARAD “Combinatorial epigenetic therapies to treat B-cell lymphomas”

2022-2023: Master 1, Calixte CALAUD “Optimising epigenetic therapies in blood cancers”

2022 (Australia): Honours, Sophia RUTAQUIO “Optimising epigenetic therapies in DLBCL”

2021 (Australia): Honours, Noura TAWFIC “Targeting deregulated epigenetic mechanisms in diffuse large B cell lymphoma”

Member of the thesis jury:

- Examinatrice:

March 2026: Giang VU TO “The role of stress signals in hematopoietic aging”

Member of the thesis monitoring committee

2024-present: James MARTIN (Université Côte d’Azur) “Decipher the impact of arginine deprivation on melanoma aggressiveness”

2025-present: Juba BENNOUR (Université Côte d’Azur) “Searching for biomarkers and potential therapeutic targets for pediatric T cell acute lymphoblastic leukemia relapse by single cell RNA sequencing analysis”

2025-present: Andrea Piero CHIERICI (Université Côte d’Azur) “ Applications de l’Intelligence Artificielle dans le cancer du pancréas pour l’analyse morphologique sur des modèles cliniques et expérimentaux”

FUNDING OF RESEARCH PROJECTS

- 2026- 2027
Grant: Université Côte d’Azur - Pole Universitaire d’Innovation Med’Innov
Amount: €45,000
Title: EPICAH
Role: Principal Investigator
- 2023 –2028
Grant: Fondation ARC 2023 - Recruiting International Leaders in Oncology
Amount: €1,480,098
Title: Deciphering the epigenetic mechanisms of blood cancer
Role: Principal Investigator
- 2023-2027
Grant: ‘Chair Of Excellence’ Labex SIGNALIFE
Amount: €600,000
Title: Epigenetic signaling in blood cancer
Role: Principal Investigator
- 2022 –2026 (*relinquished on 20/12/22*)
Grant: National Health and Medical Research Council (NHRMC) Ideas Grant (Australia)
Amount: AU\$1,111,758.80
Title: Targeting deregulated epigenetic mechanisms in lymphoma
Role: Principal Investigator
- 2019 –2022
Grant: Leukemia and Lymphoma Society (LLS) Translational Research Program (USA-Australia)
Amount: US\$600,000
Title: Targeting deregulated epigenetic mechanisms in B-cell lymphomas
Role: Key personnel
- 2016 –2018
Grant: Lymphoma Research Foundation (LRF) Postdoctoral Fellowship Grant (USA)
Amount: US\$105,000
Title: Role of TET proteins in mature B cells and lymphomagenesis
Role: Principal Investigator

OTHER ACTIVITIES

- PEER REVIEW:
 - *Cancer Research*
 - *Oncogenesis*
 - *Blood*
 - *Nature Cancer*
 - *Molecular Cancer Therapeutics*
 - *Journal of Clinical Investigation*
 - *Cell Death and Disease*

- EXPERTISE FOR AGENCIES:

- HCERES : Evaluation campaign 2023-2024

- CONFERENCES:

Organizer

2026: REencontre annuelle de Bioinformatique à Université Côte d'Azur (REBICA)

2025: Interdisciplinary conference on Multi-Omics Data Integration (MODI)

2020: Victorian Comprehensive Cancer Centre (VCCC) Alliance Postdoctoral Symposium

Chair:

2022: Chair of the Tumour Immunology session at the International Symposium on Dendritic Cells

2022: Co-chair of the ComBio Symposium on Epigenetics and Transcriptional Control.

2019: Co-chair of the session on 'Tumour Immunology & Immunotherapy' at the Meeting of the Australian Society for Immunology (ASI).

- COMMITTEES:

- Coordinator of the 'Valorization Committee' at the C3M U1065 since 2024
- Coordinator of the 'Monthly Researcher Seminars' at the C3M U10165 since 2024
- Peter Mac Postdoctoral Society (PMPS): 2019-2022
 - Leadership Committee member.
- Women in Science of Parkville Precinct (WISPP): 2019-2022
 - Grant Mentoring Program coordinator.

- OUTREACH ACTIVITIES:

- Collaboration with Polytech Nice Sophia, Diplôme d'ingénieur en Génie Biologique 2025:
 - Article in *Médecine/Science* 2025:
Ballan N, Bordji M, Degoul M, Deportes G, Hugel A, Ung S, Vernet E and Dominguez PM. Combining epigenetics and immunotherapy: an innovative strategy for acute myeloid leukemia treatment
- Community engagement: ongoing collaboration with 3 consumer representatives from the Snowdome Foundation, started in 2020.
- School Work Experience program at Peter Mac 2019-2022.
- Fund raising for the "New York Lymphoma Walk" from the Lymphoma Research Foundation (LRF) in 2016 and 2017